Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.dld.2017.06.014
Title: FABP1 and Hepar expression levels in Barrett's esophagus and associated neoplasia in an Asian population
Authors: Srivastava, Supriya 
Kern, Florian
Sharma, Neel
McKeon, Frank
Xian, Wa 
Yeoh, Khay Guan 
Ho, Khek Yu 
Teh, Ming 
Keywords: Science & Technology
Life Sciences & Biomedicine
Gastroenterology & Hepatology
Barrett's esophagus
FABP
Hepar
Esophageal adenocarcinoma
ACID-BINDING-PROTEIN
COLUMNAR-LINED ESOPHAGUS
HEPATOCELLULAR-CARCINOMA
GRADE DYSPLASIA
LIVER
ADENOCARCINOMA
MANAGEMENT
DIAGNOSIS
CARCINOGENESIS
GUIDELINES
Issue Date: 1-Oct-2017
Publisher: ELSEVIER SCIENCE INC
Citation: Srivastava, Supriya, Kern, Florian, Sharma, Neel, McKeon, Frank, Xian, Wa, Yeoh, Khay Guan, Ho, Khek Yu, Teh, Ming (2017-10-01). FABP1 and Hepar expression levels in Barrett's esophagus and associated neoplasia in an Asian population. DIGESTIVE AND LIVER DISEASE 49 (10) : 1104-1109. ScholarBank@NUS Repository. https://doi.org/10.1016/j.dld.2017.06.014
Abstract: © 2017 Introduction Barrett's esophagus (BE) is a premalignant condition associated with esophageal adenocarcinoma (EAC). Evidence highlights that EAC is associated with an estimated 5-year survival of approximately 10–15%. Therefore, there is a need to determine which biomarkers are of value in the diagnosis of BE and beyond. The aim of our study was to evaluate the clinical significance of markers known to be expressed across BE and associated neoplasia. Methods Retrospective tissues were obtained from columnar lined esophagus (CLE) without goblet cells (n = 22), BE (n = 29), dysplasia (n = 14), and EAC (n = 10). Standardised immunohistochemistry for FABP1, Hepar, CDH17, and CDX2 were performed followed by quantitative staining and statistical analysis. Results FABP1 expression was negligible in CLE and was highest in BE, with a further decrease in expression in dysplasia and EAC. Hepar expression was also negligible in CLE and was highest in dysplasia and BE, with a reduced expression in EAC. CDH17 and CDX2 showed a significantly higher expression in BE, dysplasia, and EAC compared to CLE. Conclusion All 4 markers were excellent diagnostic panels to clearly discriminate BE from CLE. Moreover, as FABP1 and Hepar have different expression levels in dysplasia and EAC, these markers could function as key diagnostic aids in helping to determine the state of disease progression.
Source Title: DIGESTIVE AND LIVER DISEASE
URI: https://scholarbank.nus.edu.sg/handle/10635/184184
ISSN: 15908658
18783562
DOI: 10.1016/j.dld.2017.06.014
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Dig Liv Disease, Oct 2017.pdf2.54 MBAdobe PDF

CLOSED

None

SCOPUSTM   
Citations

3
checked on Apr 12, 2021

Page view(s)

48
checked on Apr 15, 2021

Download(s)

3
checked on Apr 15, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.